Researchers have demonstrated a way to reshape corneal tissue using a low-level electrical current instead of cutting or removing tissue — a laboratory technique called electromechanical reshaping (EMR). This is early, ex-vivo (laboratory, non-living-eye) research, not an available treatment. No one can have this procedure today, and it has not been tested in keratoconus. It is, however, an interesting early step that is worth understanding — especially for keratoconus patients who are frequently told they are not LASIK candidates.
We previously covered this research from a general vision-correction angle in Could Electromechanical Reshaping Replace LASIK? — this article looks specifically at what it could (and could not) mean for keratoconus. Below is what was actually reported, why it caught our attention as a keratoconus-focused practice, and — just as important — what current, proven keratoconus care still looks like while this research plays out.
What the researchers did
The work was led by Michael Hill, Ph.D., of Occidental College, together with Brian Wong, M.D., Ph.D., of UC Irvine, and was presented at the American Chemical Society (ACS) Fall 2025 meeting on August 25, 2025.
The method uses a small platinum electrode shaped like a contact lens, placed against the surface of the eye. A low-level electrical current shifts the local pH of the corneal tissue, which temporarily softens the collagen that gives the cornea its shape. While softened, the cornea molds to the shape of the electrode template. When the current stops and the pH returns to normal, the collagen re-stiffens and the new shape is locked in.
In the reported experiments, the technique was used on 12 ex-vivo rabbit eyes — eyes studied outside of a living animal, in a laboratory setting. Ten of the twelve were successfully reshaped to correct a simulated myopic (nearsighted) refractive error, with treatment taking about one minute. The researchers reported no incisions and no observed loss of corneal cell viability. They also noted the reshaping appeared potentially reversible, that the approach could plausibly be far less expensive than LASIK if it is ever developed into a treatment, and that a related effect showed early promise for reducing corneal cloudiness.
Why keratoconus patients are watching
In our keratoconus clinic, the patients who ask about research like this are almost always the ones who have already been told LASIK is not an option for them — and they are right to have been told that. LASIK works by removing corneal tissue to change its curvature, and removing tissue from a cornea that is already thin and irregularly steepened, as it is in keratoconus, can worsen the ectasia. That is why LASIK is contraindicated in keratoconus.
EMR is conceptually different: it reshapes tissue that is already there rather than removing it. That is precisely why a tissue-preserving reshaping method is interesting to watch for a condition defined by tissue that is already too thin to safely remove more of. In theory, a technique that molds rather than cuts could someday be relevant to ectatic corneas in a way that LASIK cannot be.
To be direct about the limits of that idea: keratoconus was not studied in this research. The 12 eyes were normal, ex-vivo rabbit corneas used to model simple myopic correction — not thinned, irregular, ectatic corneas. Extrapolating from "this reshaped a healthy cornea" to "this could someday help an ectatic cornea" is a reasonable hypothesis for future study, not a demonstrated result. We want to be clear about that distinction rather than overstate it.
What EMR is not (yet)
- It has only been tested on ex-vivo (non-living) eyes — never in a living animal, and never in a human.
- There is no in-vivo animal safety data and no human trial data of any kind.
- It is not FDA-approved, is not offered by any clinic, and is realistically years away from human trials, if it advances that far at all.
- Open questions include long-term durability of the reshaping, safety in a living eye with blood flow, immune response, and healing, effects on the corneal endothelium (the inner cell layer that keeps the cornea clear), and whether the technique can be adapted to the irregular, asymmetric shape of an ectatic cornea rather than a simple, uniform refractive correction.
What actually works for keratoconus today
None of the above should read as a reason to wait. While EMR is studied, proven keratoconus care already exists:
- Corneal cross-linking (CXL) is the FDA-approved, standard-of-care treatment for halting keratoconus progression. It strengthens the cornea's existing collagen using UV light and riboflavin drops — it does not reshape the cornea, but it is the treatment with the strongest evidence for stopping the disease from getting worse.
- Scleral lens fitting restores clear, comfortable functional vision for many keratoconus patients by vaulting over the irregular corneal surface, regardless of how advanced the cone shape is.
- Early detection with corneal topography is what makes both of the above most effective — catching progression early gives you and your doctor the most options.
If you have keratoconus and haven't been evaluated recently, that visit — not a wait-and-see approach toward emerging research — is the useful next step.
How we'll evaluate this research
As a practice, we don't change what we recommend to patients based on a laboratory presentation. What would move the needle, in order, is: safety and reshaping data in living animal eyes over time; then human safety and efficacy trials; then an FDA review pathway specific to a corneal application. Each of those steps can fail or stall, and each one typically takes years. We'll continue to watch the peer-reviewed literature as it (if it) advances past the ex-vivo stage, and we'll update this article if that happens.
Sources
- American Chemical Society (ACS) Fall 2025 meeting, press materials and presentation abstract, August 25, 2025.
- Occidental College news coverage of Michael Hill, Ph.D.'s research collaboration with UC Irvine.
- University of California, Irvine news coverage of Brian Wong, M.D., Ph.D.'s research collaboration.
This article describes early laboratory research that is not an available treatment. It is educational and not a substitute for individualized medical advice. If you have keratoconus, discuss current, proven options with your eye doctor. Contact us with any questions.
Have Questions About Your Eye Health?
Dr. Alexander Bonakdar and his team are here to help. Schedule a consultation to discuss your specific needs.